Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. OTC Markets
  5. Synaptogenix, Inc.
  6. News
  7. Summary
    SNPX   US87167T1025

SYNAPTOGENIX, INC.

(SNPX)
  Report
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

SYNAPTOGENIX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

02/17/2021 | 07:17am EDT

Item 7.01 Regulation FD Disclosure

Synaptogenix, Inc. has prepared a presentation to be presented to investors on February 17, 2021. A copy of the investor presentation is attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 on Form 8-K, the information set forth in this Item 7.01 and the investor presentation attached to this report as Exhibit 99.1, is "furnished" and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits.


99.1 Investor Presentation of Synaptogenix, Inc., dated February 17,

           2021

© Edgar Online, source Glimpses

All news about SYNAPTOGENIX, INC.
04/30SYNAPTOGENIX, INC.  : Financial Statements and Exhibits (form 8-K)
AQ
04/26SYNAPTOGENIX  : to Present at Sachs 4th Annual Neuroscience Innovation Forum
PR
04/08SYNAPTOGENIX, INC.  : Change in Directors or Principal Officers, Submission of M..
AQ
04/01SYNAPTOGENIX  : Announces Phase 2b Bryostatin-1 Clinical Trial Update
PR
03/30SYNAPTOGE  : SYNAPTOGENIX, INC. Management's Discussion and Analysis of Financia..
AQ
02/17SYNAPTOGENIX, INC.  : Regulation FD Disclosure, Financial Statements and Exhibit..
AQ
02/12SYNAPTOGENIX  : to Participate in the Winter Wonderland - Best Ideas from the Bu..
PR
02/04SYNAPTOGENIX  : Synthetic Bryostatin Available to Expand Neurodegenerative Indic..
PR
01/22SYNAPTOGENIX, INC.  : Entry into a Material Definitive Agreement, Unregistered S..
AQ
01/19SYNAPTOGENIX, INC.  : Entry into a Material Definitive Agreement, Material Modif..
AQ
More news
Financials (USD)
Sales 2020 - - -
Net income 2020 -12,7 M - -
Net cash 2020 5,80 M - -
P/E ratio 2020 -0,50x
Yield 2020 -
Capitalization 28,1 M 28,1 M -
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees 4
Free-Float -
Chart SYNAPTOGENIX, INC.
Duration : Period :
Synaptogenix, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
NameTitle
Alan J. Tuchman Chief Executive Officer & Director
Daniel L. Alkon President, Director & Chief Science Officer
Robert Weinstein Chief Financial Officer, Secretary & Treasurer
Joshua Nathaniel Silverman Chairman
William S. Singer Vice Chairman